Brodalumab tops Stelara in Phase III psoriasis trial

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) said brodalumab showed superiority to Stelara ustekinumab from Johnson & Johnson (NYSE:JNJ) and placebo in the head-to-head Phase III AMAGINE-3 trial to treat moderate to severe plaque psoriasis.

Both 140 mg and 210 mg doses of the humanized mAb against IL17R administered every two weeks met the primary endpoint of a significantly higher proportion of patients achieving total clearance of skin disease as measured by the Psoriasis Area Severity Index (PASI 100) compared to patients treated with Stelara. Overall, 36.7% of patients in the 210 mg brodalumab arm, 27% in the 140 mg brodalumab arm and 18.5% in the Stelara arm achieved total clearance. ...